​

​

🧠 GE HealthCare Launches CleaRecon DL for Enhanced CBCT Imaging

🔬 Breakthrough/Innovation Summary:​
GE HealthCare has introduced CleaRecon DL, an AI-powered deep learning reconstruction tool designed to improve the quality of cone-beam computed tomography (CBCT) images. The system aims to reduce streak artifacts caused by pulsating blood flow and contrast distribution changes during image acquisition.

💡 Clinical/Business Impact:​
By enhancing image clarity, CleaRecon DL enables clinicians to perform procedures with greater precision and confidence, potentially leading to improved patient outcomes in interventional radiology.

📊 Relevant Data & Numbers:

• Regulatory Approvals: Received FDA 510(k) clearance and CE marking.
• Clinical Validation: In 98% of cases, CBCT images reconstructed with CleaRecon DL were clearer than conventional images.

​🔗 Read Full Article​

🌐 Korean Medical Imaging AI Companies Secure German Contracts

🔬 Breakthrough/Innovation Summary:​
South Korean AI firms Lunit and Coreline Soft have signed supply agreements with German healthcare providers to deliver advanced medical imaging solutions, including AI-powered diagnostics for cancer screening and lung disease detection.

💡 Clinical/Business Impact:​
These partnerships mark a significant step in the global expansion of Korean medical AI technologies, enhancing diagnostic capabilities and efficiency within Germany's healthcare system.

📊 Relevant Data & Numbers:

• Partnerships: Lunit with Starvision Service GmbH; Coreline Soft with Bayer.
• Scope: Deployment across multiple radiology centers and integration into national screening programs.

​🔗 Read Full Article​

💰 Pathos AI Raises $365M to Advance Solid Tumor Drug Trials

🔬 Breakthrough/Innovation Summary:​
Pathos AI has secured $365 million in Series D funding to support clinical trials of its solid tumor drug candidates, including pocenbrodib and P-500, leveraging its AI-driven platform to identify biomarkers and optimize patient selection.

💡 Clinical/Business Impact:​
The funding will accelerate the development of targeted cancer therapies, potentially improving treatment efficacy and patient outcomes in oncology.

📊 Relevant Data & Numbers:

• Funding Amount: $365 million in Series D financing.
• Valuation: Post-money valuation of approximately $1.6 billion.
• Clinical Trials: Phase 1b/2a trial of pocenbrodib; upcoming trial of P-500.

​🔗 Read Full Article​

🧪 Gyan AI Launches Hallucination-Free Research Tool for Enterprises

🔬 Breakthrough/Innovation Summary:​
Gyan AI has introduced a new AI research tool designed to eliminate hallucinations by operating solely on user-provided data, ensuring accurate and reliable outputs for enterprises in highly regulated industries.

💡 Clinical/Business Impact:​
By providing explainable and traceable insights, Gyan AI's tool enhances trust and compliance in sectors where data accuracy is paramount, such as healthcare and life sciences.

📊 Relevant Data & Numbers:

• Launch Date: May 2025.
• Key Features: Operates without pretraining; relies exclusively on client-provided data; ensures no hallucinations or biases.

​🔗 Read Full Article​

​